This article has been updated


Ewing sarcoma is an aggressive paediatric cancer of the bone and soft tissue. It results from a chromosomal translocation, predominantly t(11;22)(q24:q12), that fuses the N-terminal transactivation domain of the constitutively expressed EWSR1 protein with the C-terminal DNA binding domain of the rarely expressed FLI1 protein1. Ewing sarcoma is highly sensitive to genotoxic agents such as etoposide, but the underlying molecular basis of this sensitivity is unclear. Here we show that Ewing sarcoma cells display alterations in regulation of damage-induced transcription, accumulation of R-loops and increased replication stress. In addition, homologous recombination is impaired in Ewing sarcoma owing to an enriched interaction between BRCA1 and the elongating transcription machinery. Finally, we uncover a role for EWSR1 in the transcriptional response to damage, suppressing R-loops and promoting homologous recombination. Our findings improve the current understanding of EWSR1 function, elucidate the mechanistic basis of the sensitivity of Ewing sarcoma to chemotherapy (including PARP1 inhibitors) and highlight a class of BRCA-deficient-like tumours.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Change history

  • 27 June 2018

    In this Letter, the sentence beginning "This work was funded...." in the Acknowledgements should have read "CPRIT (RP140105) to J.C.R." rather than "CPRIT (RP150445) to J.C.R." This error has been corrected online.


Primary accessions

Gene Expression Omnibus


  1. 1.

    ., ., ., . & Chromosome study of Ewing’s sarcoma (ES) cell lines. Consistency of a reciprocal translocation t(11;22)(q24;q12). Cancer Genet. Cytogenet. 12, 1–19 (1984)

  2. 2.

    Ewing sarcoma protein: a key player in human cancer. Int. J. Cell Biol. 2013, 642853 (2013)

  3. 3.

    . et al. Ewing sarcoma gene EWS is essential for meiosis and B lymphocyte development. J. Clin. Invest. 117, 1314–1323 (2007)

  4. 4.

    . et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, D955–D961 (2013)

  5. 5.

    . & Transcription as a source of genome instability. Nat. Rev. Genet. 13, 204–214 (2012)

  6. 6.

    . et al. Homotypic and heterotypic interactions of EWS, FLI1 and their oncogenic fusion protein. Oncogene 22, 6819–6829 (2003)

  7. 7.

    ., & Ewing sarcoma fusion protein EWSR1/FLI1 interacts with EWSR1 leading to mitotic defects in zebrafish embryos and human cell lines. Cancer Res. 69, 4363–4371 (2009)

  8. 8.

    . et al. EWS, but not EWS-FLI-1, is associated with both TFIID and RNA polymerase II: interactions between two members of the TET family, EWS and hTAFII68, and subunits of TFIID and RNA polymerase II complexes. Mol. Cell. Biol. 18, 1489–1497 (1998)

  9. 9.

    ., & EWS.Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing. J. Biol. Chem. 275, 37612–37618 (2000)

  10. 10.

    & Phosphorylation and functions of the RNA polymerase II CTD. Genes Dev. 20, 2922–2936 (2006)

  11. 11.

    . et al. FUS binds the CTD of RNA polymerase II and regulates its phosphorylation at Ser2. Genes Dev. 26, 2690–2695 (2012)

  12. 12.

    . et al. Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage. Genes Dev. 28, 1957–1975 (2014)

  13. 13.

    & R loops: from transcription byproducts to threats to genome stability. Mol. Cell 46, 115–124 (2012)

  14. 14.

    ., & The Ewing sarcoma protein regulates DNA damage-induced alternative splicing. Mol. Cell 43, 353–368 (2011)

  15. 15.

    . et al. Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing. Proc. Natl Acad. Sci. USA 112, E1307–E1316 (2015)

  16. 16.

    & The contribution of co-transcriptional RNA:DNA hybrid structures to DNA damage and genome instability. DNA Repair (Amst.) 19, 84–94 (2014)

  17. 17.

    ., ., ., . & R-loop formation is a distinctive characteristic of unmethylated human CpG island promoters. Mol. Cell 45, 814–825 (2012)

  18. 18.

    . et al. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell 26, 668–681 (2014)

  19. 19.

    . et al. Efficacy of ATR inhibitors as single agents in Ewing sarcoma. Oncotarget 7, 58759–58767 (2016)

  20. 20.

    . et al. PARP-1 inhibition as a targeted strategy to treat Ewing’s sarcoma. Cancer Res. 72, 1608–1613 (2012)

  21. 21.

    . et al. Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells. J. Cell Biol. 208, 563–579 (2015)

  22. 22.

    ., ., . & XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev. 13, 2633–2638 (1999)

  23. 23.

    & Promiscuous partnerships in Ewing’s sarcoma. Cancer Genet. 204, 351–365 (2011)

  24. 24.

    . et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005)

  25. 25.

    . et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005)

  26. 26.

    . et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat. Struct. Mol. Biol. 17, 688–695 (2010)

  27. 27.

    ., ., & BRCA1 associates with processive RNA polymerase II. J. Biol. Chem. 278, 52012–52020 (2003)

  28. 28.

    . et al. BRCA1 recruitment to transcriptional pause sites is required for R-loop-driven DNA damage repair. Mol. Cell 57, 636–647 (2015)

  29. 29.

    . et al. A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. Mol. Cell 49, 872–883 (2013)

  30. 30.

    ., ., & Sarcomas: genetics, signalling, and cellular origins. Part 1: the fellowship of TET. J. Pathol. 213, 4–20 (2007)

  31. 31.

    et al. An upstream open reading frame and the context of the two AUG codons affect the abundance of mitochondrial and nuclear RNase H1. Mol. Cell. Biol. 30, 5123–5134 (2010)

  32. 32.

    et al. Prevalent, dynamic, and conserved R-loop structures associate with specific epigenomic signatures in mammals. Mol. Cell 63, 167–178 (2016)

  33. 33.

    et al. PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair. Cancer Discov. 4, 1430–1447 (2014)

  34. 34.

    et al. BRCA1 loss induces GADD153-mediated doxorubicin resistance in prostate cancer. Mol. Cancer Res. 9, 1078–1090 (2011)

  35. 35.

    et al. Profiling of the BRCA1 transcriptome through microarray and ChIP-chip analysis. Nucleic Acids Res. 39, 9536–9548 (2011)

  36. 36.

    , , & An analysis of normalization methods for Drosophila RNAi genomic screens and development of a robust validation scheme. J. Biomol. Screen. 13, 777–784 (2008)

  37. 37.

    et al. A network of conserved damage survival pathways revealed by a genomic RNAi screen. PLoS Genet. 5, e1000527 (2009)

  38. 38.

    et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005)

  39. 39.

    , & Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protocols 4, 44–57 (2009)

  40. 40.

    et al. Model-based analysis of ChIP-seq (MACS). Genome Biol. 9, R137 (2008)

  41. 41.

    et al. Computation tools for genome-wide R-loops identification and characterisation. Int. J. Comput. Biol. Drug Des. 10, 123–136 (2017)

Download references


We thank F. Chedin for the DRIP–seq protocol and genome-wide restriction enzyme sites file, and R. Crouch, J. Stark and Y. Shiio for plasmids. We are grateful to the UTH-SA/Cancer Center Sequencing core and the Histology & Immunohistochemistry Core at UTH-SA. This work was funded by the NIH (K22ES012264, 1R15ES019128, 1R01CA152063), a Voelcker Fund Young Investigator Award and CPRIT (RP150445) to A.J.R.B.; CPRIT (RP101491), a Translational Science Training Across Disciplines Scholarship (UTHSA) and an NCI postdoctoral training grant (T32CA148724) to A.G.; CPRIT (RP140105) to J.C.R.; NIH (P30CA054174) to Mays Cancer Center; NCI (R01CA204915) and Curing Kids Cancer to K.S.; NIH CTSA (1UL1RR025767-01, P30CA054174) and CPRIT (RP120685-C2) to Y.C.; NIH (1R01CA140394) to S.L.L. and NIH (1R01CA134605) to E.R.L.

Author information


  1. Department of Cell Systems and Anatomy, University of Texas Health at San Antonio, San Antonio, Texas 78229, USA

    • Aparna Gorthi
    • , July Carolina Romero
    • , Liesl A. Lawrence
    • , Xavier Bernard
    •  & Alexander J. R. Bishop
  2. Greehey Children’s Cancer Research Institute, University of Texas Health at San Antonio, San Antonio, Texas 78229, USA

    • Aparna Gorthi
    • , July Carolina Romero
    • , Eva Loranc
    • , Lin Cao
    • , Liesl A. Lawrence
    • , Elicia Goodale
    • , Xavier Bernard
    • , V. Pragathi Masamsetti
    • , Yidong Chen
    •  & Alexander J. R. Bishop
  3. Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA

    • Amanda Balboni Iniguez
    •  & Kimberly Stegmaier
  4. The Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA

    • Amanda Balboni Iniguez
    •  & Kimberly Stegmaier
  5. Departments of Oncology and Pediatrics, Georgetown University, Washington DC 20057, USA

    • Sydney Roston
    •  & Jeffrey A. Toretsky
  6. Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, Michigan 48109, USA

    • Elizabeth R. Lawlor
  7. Center for Childhood Cancer and Blood Diseases, Nationwide Children’s Hospital, Columbus, Ohio 43205, USA

    • Stephen L. Lessnick
  8. Mays Cancer Center, University of Texas Health at San Antonio, Texas 78229, USA

    • Yidong Chen
    •  & Alexander J. R. Bishop
  9. Department of Epidemiology and Biostatistics, University of Texas Health at San Antonio, San Antonio, Texas 78229, USA

    • Yidong Chen


  1. Search for Aparna Gorthi in:

  2. Search for July Carolina Romero in:

  3. Search for Eva Loranc in:

  4. Search for Lin Cao in:

  5. Search for Liesl A. Lawrence in:

  6. Search for Elicia Goodale in:

  7. Search for Amanda Balboni Iniguez in:

  8. Search for Xavier Bernard in:

  9. Search for V. Pragathi Masamsetti in:

  10. Search for Sydney Roston in:

  11. Search for Elizabeth R. Lawlor in:

  12. Search for Jeffrey A. Toretsky in:

  13. Search for Kimberly Stegmaier in:

  14. Search for Stephen L. Lessnick in:

  15. Search for Yidong Chen in:

  16. Search for Alexander J. R. Bishop in:


A.G. and A.J.R.B. conceived and designed the study and wrote the manuscript. A.G. conducted the majority of the research. J.C.R. contributed to replication of experiments for homologous recombination and BRCA1 localization. E.G. performed EU incorporation experiments. L.A.L. performed RNaseH rescue of replication stress and EU incorporation experiments. E.L., L.C., V.P.M. and X.B. provided technical support. A.B.I. and K.S. performed EWS–FLI1 knockdown for the phospho-RNAPII experiment. S.R. and J.A.T. provided recombinant EWS–FLI1 protein. Y.C. conducted bioinformatics analysis support. S.L.L. and E.R.L. provided reagents/insights.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Alexander J. R. Bishop.

Reviewer Information Nature thanks B. Braun and the other anonymous reviewer(s) for their contribution to the peer review of this work.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Supplementary information

PDF files

  1. 1.

    Supplementary Figure 1

    This file contains full scans of the western blots presented in Figures 1e-g, 2e, 3i, 4a and Extended Data Figures 1b,c, 2a,b, 3a, 5a,d, 6d-g and 7a.

  2. 2.

    Life Sciences Reporting Summary

Excel files

  1. 1.

    Supplementary Table 1

    Damage-induced changes in gene expression between IMR90 and EwS cell lines. Supplementary Table 1.1 contains a list of genes that are at least two-fold altered upon etoposide treatment in IMR90 but not in EwS cell lines. The criterion for evaluation of EwS cells was as follows: genes that were upregulated at least 2-fold in IMR90 but less than 0-fold (no change or downregulated) in EwS and vice versa. Supplementary Table 1.2 contains a list of genes that are at least two-fold altered upon etoposide treatment in EwScell lines but not in IMR90. The criterion for evaluation is as follows: genes that were upregulated at least 2-fold in EwS but less than 0-fold (no change or downregulated) in IMR90 and vice versa. Supplementary Table 1.3 contains a list of genes that were similarly altered (minimum 2-fold change) by gene expression in response to damage between IMR90 and EwS.

  2. 2.

    Supplementary Table 2

    This table shows the top 5% hits in the Drosophila kc167 RNAi screens. Data was collected as percent survival upon damage induction (3 days) for each RNAi. The loci that mapped to NCBI gene IDs are listed

About this article

Publication history





Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.